The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X-ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01 ±0.2 (°2θ), measured with a Cu-Kα irradiation (1.54060 Å), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson’s Disease and other dopamine-related disorders.本發明係關於一種羅替戈汀(Rotigotine)全新之多晶物，其特徵為，其至少具下列X射線粉末繞射圖波峰中之其中之一吸收峰，其角度為：12.04、13.68、17.72及19.01±0.2(°2θ)，其係以Cu-Kα輻射法(1.54060Å)所測，及一種用於製備該多晶物之方法，其有利於製備一穩定之藥物，用於治療或減輕巴金森氏症及其他與多巴胺有關病症之症狀。
